Immuno Cure Holding (HK) Limited
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Infectious Disease and Vaccines
Immuno Cure Holding (HK) Limited ("Immuno Cure") is a Hong Kong-based biotechnology company pioneering DNA medicine and antibody platforms for infectious diseases and cancers.
Our "PD-1-Enhanced DNA Medicine Platform" enables first-in-class therapeutics with "immune cell targeting" for long-lasting T cell immunity. Lead product ICVAX, an HIV DNA therapeutic, achieved 5- year viral suppression in macaques and completed Phase I. Entering Phase II in 2026, ICVAX aims for ART-free virological control, ultimately functional cure of HIV infection.
Our “Anti-Δ42PD1 Antibody Platform” targets a newly discovered PD-1 isoform to restore T cell functions. Candidate ORIC-001 showed promising tumor suppression in liver cancer models. Currently in IND-enabling stages, it enters human studies in 2026, with Phase I expected in 2027.
Immuno Cure seeks collaborations for out-licensing and co-development. We also invite Series B investment to support R&D and our Hong Kong Stock Exchange IPO.
Company HQ City:
Hong Kong
Company HQ State:
/
Company HQ Country:
Hong Kong
Year Founded:
2015
Lead Product in Development:
ICVAX - Our lead product ICVAX is a DNA therapeutic aiming for functional cure of HIV infection. It already achieved 5 years sustained viral suppression in macaque model and completed Phase I clinical trial with promising safety and T cell immunogenicity. ICVAX will enter Phase II efficacy trial in 2026, marking a significant step toward achieving ART-free virological control and ultimately functional cure for HIV infection.
CEO
Dr Xia JIN
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
Expected in June-August 2026.
What is your next catalyst (value inflection) update?
Our next major value kicker is the completion of a Phase I-extended efficacy clinical study of ICVAX, a DNA therapeutic for HIV infection with an aim for functional cure of HIV. Due to the announcement of promising ICVAX efficacy data, the company valuation will achieve up to USD 10 billion.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}